Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab

BACKGROUND: Ipilimumab is an FDA-approved anti-CTLA-4 monoclonal antibody used in treatment of metastatic melanoma. We present an unusual neurological complication of Ipilimumab therapy and the diagnostic dilemma it caused. CASE PRESENTATION: A 42 year old male with Stage IV metastatic melanoma deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Cafuir, Lorraine, Lawson, David, Desai, Nilesh, Kesner, Vita, Voloschin, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791192/
https://www.ncbi.nlm.nih.gov/pubmed/29382383
http://dx.doi.org/10.1186/s40425-018-0318-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5791192/
https://www.ncbi.nlm.nih.gov/pubmed/29382383
http://dx.doi.org/10.1186/s40425-018-0318-x

Ejemplares similares